Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder

20 de agosto de 2026 actualizado por: Sunshine Lake Pharma Co., Ltd.

A Phase II/III ,Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Adaptive Design Study Evaluating the Efficacy And Safety of Mitizodone Phosphate Tablets in the Treatment of Patient With Major Depressive Disorder

This is a phase 2 and 3 adaptive design study for Mitizodone Phosphate,to find out an optimal dose in phase 2 period and confirm the result an efficacy and safety in phase 3 period.Dose-finding will be done after 8 weeks of double-blinded treatment in phase 2 period and will be assessed by both efficacy and safety from 3 dose groups of Mitizodone Phosphate.The dose be found in phase 2 period will be evaluated on efficacy and safety when compared with placebo in phase 3 period with a duration of 8 weeks treatment.The target subjects are patients with MDD.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

600

Fase

  • Fase 2
  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: gang wang, Ph.D
  • Número de teléfono: 86-010-58303236
  • Correo electrónico: gangwangdoc@gmail.com

Ubicaciones de estudio

    • Guangdong
      • Dongguan, Guangdong, Porcelana, 523871
        • Reclutamiento
        • Sunshine Lake Pharma Co., Ltd.
        • Contacto:
          • Li Xue
          • Número de teléfono: +8676985315888
          • Correo electrónico: lixuelc@hec.cn

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • 1.a Man or a woman with major depressive disorder(MDD) as the primary diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria (classification code 296.22、296.23、296.32、296.33)
  • 2.Has a Montgomery Åsberg Depression Rating Scale (MADRS) total score of 26 or greater at Screening and Baseline Visits.
  • 3.Has a Clinical Global Impression - Severity of Illness (CGI-S) score of 4 or greater at Screening and Baseline Visits.

Exclusion Criteria:

  • 1.has major depressive disorder with psychotic features according to the DSM-5.
  • 2.Current or history of: bipolar disorder、schizophrenia、anixety disorder、insomnia、any substance abuse or dependence and other psychiatry disorder as defined in the DSM-5.
  • 3.Current or history of a clinically significant neurological disorder (including epilepsy、Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease).
  • 4. has Serious body disease such as neurological disorders、cardiacvascular disorders、hepatic disorders、 renal disorders, blood system disorders and endocrine disorders.
  • 5. Current or history of cancer( except basal cell of the skin and preinvasive carcinoma of cervix uteri).
  • 6. Current or history of angle-closure glaucoma.
  • 7. has made a suicide behavior in the previous 1 year ,or has a score greater than or equal to 4 on item 10 (suicidal thoughts) of MADRS .
  • 8.has taken fluoxetine within 4 weeks prior to initial dosing.
  • 9. has taken other antidepressive medications or antipsychotic medications within 2 weeks prior to initial dosing.
  • 10.has psychotherap at Screening and/or Baseline Visits.
  • 11.has had physiotherapy within 3 months prior to initial dosing.
  • 12.Has an alanine aminotransferase, aspartate aminotransferase or total bilirubin level greater than 1.5 times the upper limits of normal.
  • 13.Has an alanine aminotransferase, aspartate aminotransferase level greater than 2 times the upper limits of normal;or total bilirubin, direct bilirubin,creatinine level greater than 1.5 times the upper limits of normal;or a thyroid stimulating hormone value outside the normal range.
  • 14.Has an abnormal electrocardiogram confirmed as clinically significant by the investigator.
  • 15.Has a history of severe allergies.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Mitizodone Phosphate tablet 10mg
Mitizodone Phosphate tablet 10mg ,orally,once daily for 8 weeks, then placebo,orally,once daily for 2 weeks.
Mitizodone Phosphate tablets will be administered with food.
Otros nombres:
  • HEC113995PA•H2O
Experimental: Mitizodone Phosphate tablet 20mg
Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 7 weeks, then Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then placebo,orally,once daily for 1 weeks.
Mitizodone Phosphate tablets will be administered with food.
Otros nombres:
  • HEC113995PA•H2O
Experimental: Mitizodone Phosphate tablet 40mg
Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 40mg ,orally,once daily for 6 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks.
Mitizodone Phosphate tablets will be administered with food.
Otros nombres:
  • HEC113995PA•H2O
Comparador activo: Placebo
Placebo,tablet,orally,once daily for 10 weeks.
Placebo will be administered with food.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at week 8
Periodo de tiempo: baseline and week 8
The MADRS is a depression rating scale consisting of 10 items, each rated 0 (normal) to 6 (most abnormal). The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement.
baseline and week 8

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of subjects With a MADRS Response at Week 8
Periodo de tiempo: baseline and week 8
Response is defined as a subject with a ≥50% decrease in Montgomery Åsberg Depression Rating Scale (MADRS) total score from Baseline.
baseline and week 8
Percentage of Participants in MADRS Remission at Week 8
Periodo de tiempo: week 8
Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10.
week 8
Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at week 1、week 2 、week 4、week 6.
Periodo de tiempo: baseline 、 week 1、week 2 、week 4 and week 6.
The MADRS is a depression rating scale consisting of 10 items, each rated 0 (normal) to 6 (most abnormal). The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement.
baseline 、 week 1、week 2 、week 4 and week 6.
Change From Baseline in the Clinical Global Impression - Severity of illness (CGI-S) Total Score at week 1、week 2 、week 4、week 6、week 8.
Periodo de tiempo: baseline、week 1、week 2 、week 4、week 6 and week 8.
The Clinical Global Impression-Severity of illness scale assesses the subject's Severity as assessed by the clinician at the moment on a 8-point scale: 0, not assessed ; 1, normal,not at all ill ; 2, borderline mentally ill ; 3, mildly ill ; 4, moderately ill ; 5 , markedly ill ; 6, severely ill;7,among the most extremely ill patients.
baseline、week 1、week 2 、week 4、week 6 and week 8.
Clinical Global Impression - Improvement (CGI-I) Score at week 1、week 2 、week 4、week 6、Week 8
Periodo de tiempo: week 1、week 2 、week 4、week 6 and week 8.
The Clinical Global Impression- Improvement scale assesses the subject's improvement (or worsening) as assessed by the clinician relative to Baseline on a 8-point scale: 0, not assessed ;1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
week 1、week 2 、week 4、week 6 and week 8.
Change From Baseline in the hamilton anxiety rating scale (HAM-A)Total Score at week 1、week 2 、week 4、week 6、week 8.
Periodo de tiempo: baseline、week 1、week 2 、week 4、week 6 and week 8.
the HAM-A is a anxiety rating scale consisting of 14 items, each rated 0 (none) to 4 (very severe). The 14 items represent the core symptoms of anxiety illness. The overall score ranges from 0 (symptoms absent) to 56 (severe anxiety). A decrease in the total score or on individual items indicates improvement.
baseline、week 1、week 2 、week 4、week 6 and week 8.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

14 de diciembre de 2021

Finalización primaria (Estimado)

1 de julio de 2027

Finalización del estudio (Estimado)

1 de noviembre de 2027

Fechas de registro del estudio

Enviado por primera vez

21 de julio de 2021

Primero enviado que cumplió con los criterios de control de calidad

21 de julio de 2021

Publicado por primera vez (Actual)

30 de julio de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

20 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • HEC113995-P-5

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir